Real-World Experience With Aflibercept 8 mg in Retinal Vascular Diseases

This episode, titled “Real-World Experience with Aflibercept 8 mg in Retinal Vascular Diseases,” features panelists discussing how real-world evidence is shaping the use of aflibercept 8 mg across retinal vascular diseases, including AMD, diabetic macular edema (DME), and retinal vein occlusion (RVO). The expert faculty review findings from large IRIS Registry analyses and clinical practice experiences evaluating treatment intervals, safety, and durability outcomes in both treatment-naive and previously treated patients.

Throughout the discussion, the panel highlights how aflibercept 8 mg demonstrated comparable safety to aflibercept 2 mg while allowing many patients to achieve longer dosing intervals in routine clinical practice. The expert faculty discuss how treatment-naive patients were frequently extended to every-12-week dosing intervals, while previously treated patients often achieved an additional 2 to 3 weeks between injections after switching to aflibercept 8 mg. Panelists emphasize that even modest interval extensions may have meaningful impacts on patients receiving long-term therapy, particularly those requiring frequent injections over many years.

The panel also explores how real-world expectations may differ from clinical trial perceptions and discusses the importance of understanding what interval extension is realistically achievable in clinical practice. The expert faculty note that durability gains may appear incremental from a data perspective but can represent substantial reductions in treatment burden for patients. In addition, the discussion highlights how greater confidence in disease control and durability may allow clinicians to extend treatment intervals more comfortably while maintaining visual outcomes and minimizing the risk of fluid recurrence.

In the next episode, “Label Updates and Dosing Flexibility in Retinal Vascular Diseases,” panelists will discuss how expanded dosing flexibility with aflibercept 8 mg is influencing real-world treatment strategies across retinal vascular diseases. The expert faculty will also highlight how individualized dosing approaches and switching between next-generation anti-VEGF therapies may help optimize durability and disease control for different patient populations.